Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Vical Shares Sink After Drug Fails in Testing

By Pharmaceutical Processing | August 12, 2013

SAN DIEGO (AP) — Shares of Vical Inc. plunged 51 percent Monday after the drug developer said its potential cancer treatment failed in a late-stage study, and that it would now shift its focus to infectious disease vaccines.

Allovectin did not show a statistically significant improvement in either response rate or overall survival when compared with chemotherapy in patients with metastatic melanoma, which is an advanced form of the deadliest type of skin cancer.

Vical has several independent and collaborative infectious disease vaccine programs. The San Diego company is planning to start an early-stage study of a vaccine against herpes simplex virus type 2 before the end of the year.

Vical said it had $70 million in cash and investments as of June 30, which it believes will meet its needs at least through the end of 2014.

“In the coming weeks, we will make the necessary changes to focus resources on our infectious disease vaccine programs and reduce expenses to conserve cash,” CEO Vijay B. Samant said in a statement from the company.

Vical’s shares $1.83 to hit $1.75 before the opening bell. The shares had climbed 23 percent so far in 2013 as of Friday’s closing price of $3.58.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE